MedTrace Logo

Mipolixin® Compared to Poliprotect® in Moderate Functional Dyspepsia and Heartburn.

NCT03531372 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 158

Last updated 2021-05-26

No results posted yet for this study

Summary

Evaluation of the clinical efficacy of two medical devices, Mipolixin® and Poliprotect®, in improving the overall symptom severity of functional dyspesia and/or heartburn

Conditions

  • Dyspepsia
  • Heartburn

Interventions

DEVICE

Mipolixin®

1.55g chewable tablet 5 times a day for 2 weeks

DEVICE

Poliprotect®

1.55 g chewable tablet 5 times a day for 2 weeks

Sponsors & Collaborators

  • La Sociedad Española de Médicos de Atención Primaria

    collaborator OTHER

  • Dynamic

    collaborator UNKNOWN

  • Aboca Spa Societa' Agricola

    lead INDUSTRY

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2018-04-24
Primary Completion
2021-04-30
Completion
2021-04-30

Countries

  • Spain

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03531372 on ClinicalTrials.gov